{"schema_version":"alpha-governance-record-v2","alpha_id":"alpha:company:470d407f-5f6c-4739-98b3-489250171379","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce","ontology_version":"alpha-governance-ontology-v1","as_of":"2026-10-17T04:41:50.693666+00:00","published_at":"2026-10-16T13:53:12.75153+00:00","section":"events","data":{"state":"PUBLISHED","derivation_version":"alpha-governance-event-derivation-v2","events":[{"event_id":"alpha:event:transition:14ct6mufc1s9m","event_type":"DIRECTOR_APPOINTED","effective_at":"2024-01-01","detected_at":"2026-10-16T13:53:12.75153+00:00","subject_ids":["alpha:person:ivana-magovevic-liebisch-ph-d-j-d","alpha:company:470d407f-5f6c-4739-98b3-489250171379"],"caused_claim_ids":["alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:9"],"evidence_ids":["alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417"],"summary":"Ivana Magovevic-Liebisch, Ph.D., J.D. seat on Acrivon Therapeutics, Inc., effective 2024-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1k3po1z3yr9x1","event_type":"DIRECTOR_APPOINTED","effective_at":"2024-01-01","detected_at":"2026-10-16T13:53:12.75153+00:00","subject_ids":["alpha:person:santhosh-palani-ph-d-c-f-a","alpha:company:470d407f-5f6c-4739-98b3-489250171379"],"caused_claim_ids":["alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:13"],"evidence_ids":["alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417"],"summary":"Santhosh Palani, Ph.D., CFA seat on Acrivon Therapeutics, Inc., effective 2024-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:ad6ybdvwq2gf","event_type":"DIRECTOR_APPOINTED","effective_at":"2023-01-01","detected_at":"2026-10-16T13:53:12.75153+00:00","subject_ids":["alpha:person:charles-baum-m-d-ph-d","alpha:company:470d407f-5f6c-4739-98b3-489250171379"],"caused_claim_ids":["alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:7"],"evidence_ids":["alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417"],"summary":"Charles Baum, M.D., Ph.D. seat on Acrivon Therapeutics, Inc., effective 2023-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:4y6t77a1tkuh","event_type":"DIRECTOR_APPOINTED","effective_at":"2022-01-01","detected_at":"2026-10-16T13:53:12.75153+00:00","subject_ids":["alpha:person:michael-tomsicek-m-b-a","alpha:company:470d407f-5f6c-4739-98b3-489250171379"],"caused_claim_ids":["alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:11"],"evidence_ids":["alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417"],"summary":"Michael Tomsicek, M.B.A. seat on Acrivon Therapeutics, Inc., effective 2022-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1rgapjg1x5e7c2","event_type":"DIRECTOR_APPOINTED","effective_at":"2021-01-01","detected_at":"2026-10-16T13:53:12.75153+00:00","subject_ids":["alpha:person:derek-dirocco-ph-d","alpha:company:470d407f-5f6c-4739-98b3-489250171379"],"caused_claim_ids":["alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417"],"summary":"Derek DiRocco, Ph.D. seat on Acrivon Therapeutics, Inc., effective 2021-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:8tkv041azd7ry","event_type":"DIRECTOR_APPOINTED","effective_at":"2020-01-01","detected_at":"2026-10-16T13:53:12.75153+00:00","subject_ids":["alpha:person:sharon-shacham-ph-d-m-b-a","alpha:company:470d407f-5f6c-4739-98b3-489250171379"],"caused_claim_ids":["alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:14"],"evidence_ids":["alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417"],"summary":"Sharon Shacham, Ph.D., M.B.A. seat on Acrivon Therapeutics, Inc., effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:58rbe33ptn4h","event_type":"DIRECTOR_APPOINTED","effective_at":"2018-01-01","detected_at":"2026-10-16T13:53:12.75153+00:00","subject_ids":["alpha:person:kristina-masson-ph-d-m-b-a","alpha:company:470d407f-5f6c-4739-98b3-489250171379"],"caused_claim_ids":["alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:10"],"evidence_ids":["alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417"],"summary":"Kristina Masson, Ph.D., M.B.A. seat on Acrivon Therapeutics, Inc., effective 2018-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1sxxskn1lf2eav","event_type":"DIRECTOR_APPOINTED","effective_at":"2018-01-01","detected_at":"2026-10-16T13:53:12.75153+00:00","subject_ids":["alpha:person:peter-blume-jensen-m-d-ph-d","alpha:company:470d407f-5f6c-4739-98b3-489250171379"],"caused_claim_ids":["alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:12"],"evidence_ids":["alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417"],"summary":"Peter Blume-Jensen, M.D., Ph.D. seat on Acrivon Therapeutics, Inc., effective 2018-01-01.","derivation":"temporal_relationship_change"}]},"claims":[{"id":"alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:7","subject_id":"alpha:company:470d407f-5f6c-4739-98b3-489250171379","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:charles-baum-m-d-ph-d","object_label":"Charles Baum, M.D., Ph.D.","object_source_name_forms":[],"value":"Charles Baum, M.D., Ph.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:charles-baum-m-d-ph-d","name":"Charles Baum, M.D., Ph.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2023-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2023-01-01","valid_to":null,"recorded_at":"2026-10-16T13:53:12.75153+00:00","sources":[{"id":"alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_date":"2025-04-25","retrieved_at":"2026-04-24T20:10:02.508+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-04-25","effective_from":"2023-01-01","effective_until":null,"observed_at":"2026-10-16T13:53:12.75153+00:00","reviewed_at":"2026-10-16T13:53:12.75153+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:8","subject_id":"alpha:company:470d407f-5f6c-4739-98b3-489250171379","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:derek-dirocco-ph-d","object_label":"Derek DiRocco, Ph.D.","object_source_name_forms":[],"value":"Derek DiRocco, Ph.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:derek-dirocco-ph-d","name":"Derek DiRocco, Ph.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-16T13:53:12.75153+00:00","sources":[{"id":"alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_date":"2025-04-25","retrieved_at":"2026-04-24T20:10:02.508+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-04-25","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-16T13:53:12.75153+00:00","reviewed_at":"2026-10-16T13:53:12.75153+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:9","subject_id":"alpha:company:470d407f-5f6c-4739-98b3-489250171379","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:ivana-magovevic-liebisch-ph-d-j-d","object_label":"Ivana Magovevic-Liebisch, Ph.D., J.D.","object_source_name_forms":[],"value":"Ivana Magovevic-Liebisch, Ph.D., J.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:ivana-magovevic-liebisch-ph-d-j-d","name":"Ivana Magovevic-Liebisch, Ph.D., J.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2024-01-01","valid_to":null,"recorded_at":"2026-10-16T13:53:12.75153+00:00","sources":[{"id":"alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_date":"2025-04-25","retrieved_at":"2026-04-24T20:10:02.508+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-04-25","effective_from":"2024-01-01","effective_until":null,"observed_at":"2026-10-16T13:53:12.75153+00:00","reviewed_at":"2026-10-16T13:53:12.75153+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:10","subject_id":"alpha:company:470d407f-5f6c-4739-98b3-489250171379","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:kristina-masson-ph-d-m-b-a","object_label":"Kristina Masson, Ph.D., M.B.A.","object_source_name_forms":[],"value":"Kristina Masson, Ph.D., M.B.A.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:kristina-masson-ph-d-m-b-a","name":"Kristina Masson, Ph.D., M.B.A."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2018-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2018-01-01","valid_to":null,"recorded_at":"2026-10-16T13:53:12.75153+00:00","sources":[{"id":"alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_date":"2025-04-25","retrieved_at":"2026-04-24T20:10:02.508+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-04-25","effective_from":"2018-01-01","effective_until":null,"observed_at":"2026-10-16T13:53:12.75153+00:00","reviewed_at":"2026-10-16T13:53:12.75153+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:11","subject_id":"alpha:company:470d407f-5f6c-4739-98b3-489250171379","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:michael-tomsicek-m-b-a","object_label":"Michael Tomsicek, M.B.A.","object_source_name_forms":[],"value":"Michael Tomsicek, M.B.A.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:michael-tomsicek-m-b-a","name":"Michael Tomsicek, M.B.A."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2022-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2022-01-01","valid_to":null,"recorded_at":"2026-10-16T13:53:12.75153+00:00","sources":[{"id":"alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_date":"2025-04-25","retrieved_at":"2026-04-24T20:10:02.508+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-04-25","effective_from":"2022-01-01","effective_until":null,"observed_at":"2026-10-16T13:53:12.75153+00:00","reviewed_at":"2026-10-16T13:53:12.75153+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:12","subject_id":"alpha:company:470d407f-5f6c-4739-98b3-489250171379","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:peter-blume-jensen-m-d-ph-d","object_label":"Peter Blume-Jensen, M.D., Ph.D.","object_source_name_forms":[],"value":"Peter Blume-Jensen, M.D., Ph.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:peter-blume-jensen-m-d-ph-d","name":"Peter Blume-Jensen, M.D., Ph.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2018-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2018-01-01","valid_to":null,"recorded_at":"2026-10-16T13:53:12.75153+00:00","sources":[{"id":"alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_date":"2025-04-25","retrieved_at":"2026-04-24T20:10:02.508+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-04-25","effective_from":"2018-01-01","effective_until":null,"observed_at":"2026-10-16T13:53:12.75153+00:00","reviewed_at":"2026-10-16T13:53:12.75153+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:13","subject_id":"alpha:company:470d407f-5f6c-4739-98b3-489250171379","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:santhosh-palani-ph-d-c-f-a","object_label":"Santhosh Palani, Ph.D., CFA","object_source_name_forms":[],"value":"Santhosh Palani, Ph.D., CFA: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:santhosh-palani-ph-d-c-f-a","name":"Santhosh Palani, Ph.D., CFA"},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2024-01-01","valid_to":null,"recorded_at":"2026-10-16T13:53:12.75153+00:00","sources":[{"id":"alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_date":"2025-04-25","retrieved_at":"2026-04-24T20:10:02.508+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-04-25","effective_from":"2024-01-01","effective_until":null,"observed_at":"2026-10-16T13:53:12.75153+00:00","reviewed_at":"2026-10-16T13:53:12.75153+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:470d407f-5f6c-4739-98b3-489250171379:leadership_role:14","subject_id":"alpha:company:470d407f-5f6c-4739-98b3-489250171379","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:sharon-shacham-ph-d-m-b-a","object_label":"Sharon Shacham, Ph.D., M.B.A.","object_source_name_forms":[],"value":"Sharon Shacham, Ph.D., M.B.A.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:sharon-shacham-ph-d-m-b-a","name":"Sharon Shacham, Ph.D., M.B.A."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-16T13:53:12.75153+00:00","sources":[{"id":"alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_date":"2025-04-25","retrieved_at":"2026-04-24T20:10:02.508+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-04-25","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-16T13:53:12.75153+00:00","reviewed_at":"2026-10-16T13:53:12.75153+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"}],"evidence":[{"id":"alpha:projection-evidence:document:7bbfae301adc08c5d9a8820a472c28a70e102d15a5cc83f6823825705073b417","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_date":"2025-04-25","retrieved_at":"2026-04-24T20:10:02.508+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"coverage_state":"PUBLISHED","quality":{"schema_version":"alpha-record-quality-v2","overall":0.826,"status":"strong","publication_readiness":"ready","dimensions":{"identity":1,"coverage":0.5,"freshness":1,"evidence_completeness":1,"source_authority":0.85,"cross_source_agreement":0.75,"temporal_completeness":0.471},"diagnostics":{"published_claims":26,"factual_claims":26,"claims_with_linked_evidence":26,"disputed_claims":0,"conflicts":0,"stale_claims":0,"stale_claim_ids":[],"temporal_claims":17,"temporal_claims_with_valid_from":8,"missing_coverage_sections":["governance","financials","workforce","ownership","ratings"],"missing_expected_claims":["headquarters","official_website","executive_role","financial_metric","governance_document","ownership","auditor","legal_matter","risk","ai_governance"]},"derivation":"deterministic_record_projection"},"publication":{"state":"PUBLISHED","published_at":"2026-10-16T13:53:12.75153+00:00","observed_at":"2026-10-16T13:53:12.75153+00:00","reviewed_at":"2026-10-16T13:53:12.75153+00:00","verified_at":"2026-10-16T13:53:12.75153+00:00"},"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":26,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed.","facets":[{"facet":"identity","state":"unclaimed"},{"facet":"evidence","state":"source_reported"},{"facet":"evaluation","state":"not_evaluated"},{"facet":"monitoring","state":null},{"facet":"authority","state":null},{"facet":"freshness","state":"current"}]},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"},"resource":{"uri":"alpha://company/acrivon-therapeutics-inc/events","section":"events","href":"https://registry.alpha.ac/api/public/companies/acrivon-therapeutics-inc?format=record&section=events","media_type":"application/json","availability":"contract"},"limitations":["Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."]}